Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06997029 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
234
Enrollment target
20
Study locations

NCT06997029: Recruiting Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer, sponsored by Bristol-Myers Squibb.

NCT06997029 is a Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 234 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06997029, a Phase 1 study of Advanced Solid Tumor and Advanced Breast Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
234 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Conditions Studied

Advanced Solid Tumor Advanced Breast Cancer Advanced Ovarian Cancer

Interventions

  • DRUG Fulvestrant
  • DRUG Palbociclib
  • DRUG BMS-986500

Study Locations (20)

California

  • Providence St. Jude Medical Center - Fullerton
  • Marin Cancer Care - Greenbrae
  • Moores Cancer Center - La Jolla
  • Hoag Memorial Hospital Presbyterian - Newport Beach

New York

  • Local Institution - 0014 - Buffalo
  • Northwell Health-Cancer Institute - New Hyde Park
  • Local Institution - 0011 - New York
  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • START Dallas Fort Worth - Fort Worth
  • NEXT Oncology - San Antonio

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • Local Institution - 0008 - Aurora

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 234 participants
Start Date 2025-08-01
Est. Completion 2028-12-14
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What NCT06997029 shows while recruiting

NCT06997029 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher).

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Fulvestrant is the first listed.

NCT06997029 names 20 study sites across 13 states, led by California, New York, Texas.

Frequently Asked Questions

What is clinical trial NCT06997029 about?

NCT06997029 is a clinical study titled "A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors". The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

What is the current status of trial NCT06997029?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2025-08-01. Estimated completion is 2028-12-14.

What conditions does trial NCT06997029 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer.

What interventions are being tested in trial NCT06997029?

The interventions under investigation include: Fulvestrant (DRUG), Palbociclib (DRUG), BMS-986500 (DRUG).

Who is sponsoring clinical trial NCT06997029?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06997029 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06997029's enrollment target sits among peer trials

234 52nd of 189 higher than 137 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04942717 · 234 participants · NA

    Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

  • NCT05208671 · 234 participants · NA

    Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

  • NCT05444465 · 234 participants · NA

    Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

  • NCT05720338 · 234 participants · Phase 3

    Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06997029

Source: ClinicalTrials.gov NCT06997029, the US trial registry maintained by the National Library of Medicine. NCT06997029 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.